ArticleCell reports2021
Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING.
Open access · goldAbstract read
In one paragraph
Article in Cell reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers.
0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed
8.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
84 citing papers in PubMed, 132 citations in OpenAlex.
- The dual immune landscape of homologous recombination-deficient tumors: mechanisms and therapeutic implications.Cancer metastasis reviews · 2026Review
- A versatile cGAMP reporter reveals principles of cGAS activation by DNA damage and chromosome instability.Nature cell biology · 2026Article
- BRCA1 deficiency induces NFκB-dependent type-I interferon signaling in fallopian tube epithelial cells.Neoplasia (New York, N.Y.) · 2026Article
- Article
- Combinatorial Delivery of Low-Dose Radiotherapy and Immunotherapy to Patients with Immune-Excluded Tumors Enhances CD8+ T-cell Functionality.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Choline metabolism drives metastasis in BRCA1-deficient ovarian cancers by activating FAM3C.Nature communications · 2026Article
- Advances in immunotherapies in ovarian cancer.Journal for immunotherapy of cancer · 2026Review
- Article
- Detection of nuclear STING in cultured human cells and in the normal and cancer tissues.iScience · 2026Article
- Distinct immune microenvironments in ovarian cancer subtypes indicate potential for immunotherapies.Journal of translational medicine · 2026Article
- Inflammatory milieu and role of epigenetic modifications in high-grade serous ovarian cancer.Clinical epigenetics · 2026Review
- Next Generation DNA Damage Response Inhibitors: Harnessing Nanocarriers and Tumor Microenvironment for Precision Cancer Therapy.Oncology research · 2026Review
- The cGAS-STING pathway in cancer immunotherapy: prognostic value and therapeutic potential.Frontiers in immunology · 2026Review
- Integrating chronic inflammation and hypoxia: the potential role of HIF-1α in tumor behavior and therapy response in high-grade serous ovarian cancer.Frontiers in immunology · 2026Article
- Fallopian tube lavage sampling towards early detection of pre-invasive ovarian cancer.Clinical and translational medicine · 2026Article
- Breaking barriers: The cGAS-STING pathway as a novel frontier in cancer immunotherapy.Cancer communications (London, England) · 2025Review
- Tissue specificity and chromosomal alterations shape divergent immune programs in HRD tumors.bioRxiv : the preprint server for biology · 2025Article
- PARP inhibitor-induced anti-tumour chemokine response is suppressed by dipeptidyl peptidase 4 (DPP4) in ovarian cancer.British journal of cancer · 2025Article
- The distinct landscape of tumor immune microenvironment in homologous recombination deficient cancers.Biomarker research · 2025Review
- Unlocking the therapeutic potential of the STING signaling pathway in anti-tumor treatment.Clinical and experimental medicine · 2025Review
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors at 7 institutions in 6 countries.
Marine BruandLudwig Institute for Cancer Research, University Hospital of Lausanne (CHUV), Lausanne, Switzerland.
David BarrasLudwig Institute for Cancer Research, University Hospital of Lausanne (CHUV), Lausanne, Switzerland; Swiss Institute of Bioinformatics, Lausanne, Switzerland.
Marco MinaSwiss Institute of Bioinformatics, Lausanne, Switzerland; Department of Computational Biology, UNIL, Lausanne, Switzerland.
Eleonora GhisoniLudwig Institute for Cancer Research, University Hospital of Lausanne (CHUV), Lausanne, Switzerland.
Matteo MorottiLudwig Institute for Cancer Research, University Hospital of Lausanne (CHUV), Lausanne, Switzerland.
Evripidis LanitisLudwig Institute for Cancer Research, University Hospital of Lausanne (CHUV), Lausanne, Switzerland.
Noémie FahrLudwig Institute for Cancer Research, University Hospital of Lausanne (CHUV), Lausanne, Switzerland.
Mathieu DesbuissonLudwig Institute for Cancer Research, University Hospital of Lausanne (CHUV), Lausanne, Switzerland.
Alizée GrimmLudwig Institute for Cancer Research, University Hospital of Lausanne (CHUV), Lausanne, Switzerland.
Hualing ZhangLudwig Institute for Cancer Research, University Hospital of Lausanne (CHUV), Lausanne, Switzerland; Department of Gynecology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Chloe ChongLudwig Institute for Cancer Research, University Hospital of Lausanne (CHUV), Lausanne, Switzerland.
Julien DagherInstitute of Pathology, University Hospital of Lausanne (CHUV), Lausanne, Switzerland.
Sora CheeLudwig Institute for Cancer Research and University of California, La Jolla, CA, USA.
Theodora TsianouLudwig Institute for Cancer Research, University Hospital of Lausanne (CHUV), Lausanne, Switzerland.
Julien DorierSwiss Institute of Bioinformatics, Lausanne, Switzerland; Bioinformatics Competence Center, University of Lausanne, Lausanne, Switzerland.
Brian J StevensonSwiss Institute of Bioinformatics, Lausanne, Switzerland.
Christian IseliSwiss Institute of Bioinformatics, Lausanne, Switzerland.
Catherine RonetLudwig Institute for Cancer Research, University Hospital of Lausanne (CHUV), Lausanne, Switzerland.
Sara BobisseLudwig Institute for Cancer Research, University Hospital of Lausanne (CHUV), Lausanne, Switzerland.
Raphael GenoletLudwig Institute for Cancer Research, University Hospital of Lausanne (CHUV), Lausanne, Switzerland.
Josephine WaltonDepartment of Surgery & Cancer, Ovarian Cancer Action Research Centre, Hammersmith Hospital, Imperial College London, London, UK.
Michal Bassani-SternbergLudwig Institute for Cancer Research, University Hospital of Lausanne (CHUV), Lausanne, Switzerland.
Lana E KandalaftLudwig Institute for Cancer Research, University Hospital of Lausanne (CHUV), Lausanne, Switzerland.
Bing RenLudwig Institute for Cancer Research and University of California, La Jolla, CA, USA.
Iain McNeishDepartment of Surgery & Cancer, Ovarian Cancer Action Research Centre, Hammersmith Hospital, Imperial College London, London, UK.
Elizabeth SwisherDepartment of Oncology, Washington University, Seattle, WA, USA.
Alexandre HarariLudwig Institute for Cancer Research, University Hospital of Lausanne (CHUV), Lausanne, Switzerland.
Mauro DelorenziLudwig Institute for Cancer Research, University Hospital of Lausanne (CHUV), Lausanne, Switzerland; Swiss Institute of Bioinformatics, Lausanne, Switzerland.
Giovanni CirielloSwiss Institute of Bioinformatics, Lausanne, Switzerland; Department of Computational Biology, UNIL, Lausanne, Switzerland.
Melita IrvingLudwig Institute for Cancer Research, University Hospital of Lausanne (CHUV), Lausanne, Switzerland.
Sylvie RusakiewiczLudwig Institute for Cancer Research, University Hospital of Lausanne (CHUV), Lausanne, Switzerland.
Periklis G Foukas2nd Department of Pathology, Attikon Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Fabio MartinonDepartment of Biochemistry, UNIL, Lausanne, Switzerland.
Denarda Dangaj LanitiLudwig Institute for Cancer Research, University Hospital of Lausanne (CHUV), Lausanne, Switzerland. Electronic address: denarda.dangaj@chuv.ch.
George CoukosLudwig Institute for Cancer Research, University Hospital of Lausanne (CHUV), Lausanne, Switzerland. Electronic address: george.coukos@chuv.ch.
University Hospital of Lausanne · CHSIB Swiss Institute of Bioinformatics · CHHammersmith Hospital · GBLudwig Cancer Research · USNational and Kapodistrian University of Athens · GRQingdao University · CNUniversity of Lausanne · CH
Funding
Therapeutic Micro RNA Strategies for Ovarian CancerP50CA083638 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI DALY, MARY BERYL, REBBECK, TIMOTHY R · 1999 to 2013
$33.6MUsing Integrated Omics to Identify Dysfunctional Genetic Mechanisms Influencing Schizophrenia and Sleep DisturbancesP20GM130423 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Kalyani Pyaram, Steven Allan Soper · 2019 to 2026
$21.5MNCI NIH HHS P50 CA083638NIGMS NIH HHS P20 GM130423
Abstract
In this study, we investigate mechanisms leading to inflammation and immunoreactivity in ovarian tumors with homologous recombination deficiency (HRD). BRCA1 loss is found to lead to transcriptional reprogramming in tumor cells and cell-intrinsic inflammation involving type I interferon (IFN) and stimulator of IFN genes (STING). BRCA1-mutated (BRCA1
Indexed as
AnimalsBRCA1 ProteinCell Line, TumorChemokine CCL5ChromatinDNADNA DamageEpigenesis, GeneticFemaleGene SilencingHumansImmune Checkpoint InhibitorsInflammationInterferonsMembrane ProteinsMiceBRCA1 ProteinBRCA1 protein, humanChemokine CCL5ChromatinDNAImmune Checkpoint InhibitorsInterferonsMembrane ProteinsProtein Serine-Threonine KinasesSTING1 protein, humanSTING ProteinTBK1 protein, humanVascular Endothelial Growth Factor AangiogenesisBRCA1CTLA-4DNA sensingdual immune checkpoint blockadeICBovarian cancerPARPiPD-L1STINGT cellstype I IFNVEGF-A
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.